http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2394274-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa8aac9dfa2ae1357007208f2963a275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D219-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C233-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D219-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D219-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-82 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D237-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D219-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-42 |
| filingDate | 2007-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_409a14599f1de04df185d28ee1122d9f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fc122bfdc9d7942388a9d2df7051910 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_347d34ca11ae0693aad0050bf7c87045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c441240cc00adef46fffae8178193ab4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7cc6b5ebeb13ac476b30b001e7a40ee |
| publicationDate | 2013-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2394274-T3 |
| titleOfInvention | Halobenzamide labeled analogs such as radiopharmaceuticals |
| abstract | Compound of formula (I): in which R1 represents a radionuclide, Ar is a heteroaryl group, m is an integer ranging from 2 to 4, R2 and R3 represent, independently of each other, a hydrogen atom, an alkyl group (C1-C6) or an (C1-C6) alkenyl group, wherein the heteroaryl group is a 5 or 6 membered aromatic ring, comprising 1 or 2 nitrogen atoms, or a bi- or tricyclic aromatic nucleus comprising from 1 to 4 nitrogen atoms or comprising a sulfur atom, having at least one of the rings 6 annular members, the other ring or condensed rings having 5 or 6 annular members, it being possible that said heteroaryl group is monosubstituted by: - an optionally labeled halogen atom, - a (C1-C4) alkoxy group, - a (C1-C4) alkyl group, - an oxo group, or - an aniline group, which may itself be substituted by 1 to 3 groups, which can be selected from a (C1-C4) alkyl group or a (C1-C4) alkoxy group, a hydroxyl group, a halogen atom or an NHRe group, in which Re represents a hydrogen, or a CORa group, a COORa group or a SO2Ra group, in which Ra represents a group aryl or a (C1-C10) alkyl group optionally substituted with an oxo group; and wherein R1 is linked to the aromatic nucleus as such, or, when the aromatic nucleus substituent is an aniline group, R1 may be linked to the phenyl group of the anilino group, and in which Ar is selected from a group pyridyl, phenazinyl, naphthyridinyl, indolyl, imidazopyridyl, benzimidazolyl, quinolyl, quinolonyl, isoquinolyl, quinoxalinyl, benzothienyl, acridinyl or acridonyl, it being possible that said group is monosubstituted by a methyl group, a methoxy group or an optionally labeled methoxy group an acridinyl group substituted by an anilino group which may itself be substituted by between 1 and 3 groups that can be selected from a (C1-C4) alkyl or (C1-C4) alkoxy group, a hydroxyl group, an atom of halogen or an NHRc group, in which Re represents a hydrogen, or a CORa group, a COORa group or a SO2Ra group, in which Ra represents an aryl group or an optionally substituted (C1-C10) alkyl group by an oxo group, and its addition salts with pharmaceutically acceptable acids, for use in a radiopharmaceutical composition in the diagnosis and / or treatment of melanoma. |
| priorityDate | 2006-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 431.